Rapid test to assess the escape of SARS-CoV-2 variants of concern

 JACOB T. HEGGESTAD HTTPS://ORCID.ORG/0000-0001-5217-6735RHETT J. BRITTON HTTPS://ORCID.ORG/0000-0002-2411-3195DAVID S. KINNAMON HTTPS://ORCID.ORG/0000-0001-9463-6613SIMONE A. WALLDANIEL Y. JOHANGUS M. HUCKNALLLYRA B. OLSON HTTPS://ORCID.ORG/0000-0003-2783-8244JACK G. ANDERSONANNA MAZUR[...]ASHUTOSH CHILKOTI HTTPS://ORCID.ORG/0000-0002-1569-2228  Authors Info & Affiliations

DOI: 10.1126/sciadv.abl7682





PDF: https://www.science.org/doi/epdf/10.1126/sciadv.abl7682?adobe_mc=MCMID%3D73246005249468380041472861452220386286%7CMCORGID%3D242B6472541199F70A4C98A6%2540AdobeOrg%7CTS%3D1638660732

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1. Using CoVariant-SCAN, we assessed neutralization/blocking of monoclonal antibodies and plasma from COVID-19–positive and vaccinated individuals. For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized. We also showed that we can rapidly adapt the platform to detect nAbs against an additional variant—B.1.617.2 (Delta)—without reengineering or reoptimizing the assay. Results using CoVariant-SCAN are consistent with live virus neutralization assays and demonstrate that this easy-to-deploy test could be used to rapidly assess nAb response against multiple SARS-CoV-2 variants.

https://www.science.org/doi/10.1126/sciadv.abl7682